NCT04374799 Heparin vs Placebo for Cardiac Catheterization
| NCT ID | NCT04374799 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's |
| Condition | Cardiac Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,623 participants |
| Start Date | 2020-10-05 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 1,623 participants in total. It began in 2020-10-05 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients undergoing cardiac catheterization will be randomized to 3 groups: no anticoagulant, low dose anticoagulant and high dose anticoagulant.
Eligibility Criteria
Inclusion Criteria: * diagnostic cardiac catheterization; Small size sheath; patency of the ulno-palmar circulation Exclusion Criteria: abnormal ulno-palmar circulation; Prior radial artery thrombosis; Prior surgery close to the access site; Emergent cardiac catheterization; History of HIT or allergy to heparin; Patients requiring anticoagulation
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04374799 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiac Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT04374799 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 1,623 participants.
Is NCT04374799 currently recruiting?
Yes, NCT04374799 is actively recruiting participants. Contact the research team at Shahar.lavi@lhsc.on.ca for enrollment information.
Where is the NCT04374799 trial being conducted?
This trial is being conducted at Hamilton, Canada, London, Canada.
Who is sponsoring the NCT04374799 clinical trial?
NCT04374799 is sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. The trial plans to enroll 1,623 participants.